Amarin (AMRN) Volatility Nearly Double into PDUFA for AMR101
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp. (Nasdaq: AMRN) volatility is slightly elevated on the session, but at 9 percent is nearly double the trailing annual average, heading into the pharma's PDUFA date tomorrow (July 26th) for AMR101.
Today, Amarin received notice of intention to grant letter for European Patent Application Number EP2395991, titled "Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia."
Amarin noted that this patent application "is intended to protect the exclusivity of Amarin's drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA)."
Shares of Amarin hit a new 52-week high last Thursday, and have held above at the upper-quarter of $14 or above since.
Today, Amarin received notice of intention to grant letter for European Patent Application Number EP2395991, titled "Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia."
Amarin noted that this patent application "is intended to protect the exclusivity of Amarin's drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA)."
Shares of Amarin hit a new 52-week high last Thursday, and have held above at the upper-quarter of $14 or above since.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin highlights Vascepa cost advantage over new injectable rivals
- Global S&P Futures mixed in premarket
- FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
Create E-mail Alert Related Categories
FDA, Insiders' Blog, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
